- 0
About Us
Clinical research site that offers consulting services to Pharmaceutical and Biotechnological Companies
Download Video: MP4, HTML5 Video Player by VideoJS
Easy Access from the US
Info on non-stop flights from the most important cities in the U.S., Hotel reservations & more...
Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico
Virus-like particles (VLPs) can be rapidly developed from influenza virus genetic sequences in order to supply vaccine after the onset of a pandemic. The safety and immunogenicity of one or two doses of a recombinant A (H1N1) 2009 influenza VLP vaccine was evaluated in a two-stage, Phase 2, randomized, double-blind, placebo-controlled study conducted in 4563 healthy adults, 18–64 years of age, during the H1N1 2009 pandemic in Mexico.
Text by: Constantino López-Macíasa, Eduardo Ferat-Osorio, Alejandra Tenorio-Calvol, Armando Isibasi, Juan Talavera, Oscar Arteaga-Ruiz, Lourdes Arriaga-Pizano, Somia P. Hickman, María Allende, Kathy Lenhard, Steven Pincus, Kevin Connolly, Ramadevi Raghunandan, Gale Smith, Gregory Glenn
